
News|Slideshows|March 25, 2019
ACC.19: 3 Studies in Cardioprotection
Author(s)Veronica Hackethal, MD
Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis
2
Why Prostate Cancer Screening Belongs in Primary Care
3
FDA Accepts Extended Duration sNDA for Miudella Hormone-Free IUD
4
Migraine, Estrogen, and Pregnancy Shape Stroke Risk in Women
5























































































































































